13F Holdings
中文EN

GLUE Monte Rosa Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1826457 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-61.3%
TTM net income YoY-725.3%
TTM EPS YoY-574.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-214.5%
Net margin-186.2%
FCF margin-248.0%
EBITDA margin-202.8%

Returns

ROE-35.3%
ROA-22.6%
ROIC (approx.)-48.8%
Asset turnover0.12x

Leverage & solvency

Liabilities / assets28.9%
Debt / equity0.00x
Current ratio10.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio6.0%
Payout ratio—
Capex / revenue12.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$123.67M$75.62M$0——
R&D expense$141.50M$121.56M$111.27M$85.06M$57.16M
SG&A expense$36.38M$35.17M$32.04M$27.32M$15.73M
Operating income-$54.21M-$81.11M-$143.31M-$112.38M-$72.88M
Pretax income-$39.72M-$70.13M-$135.01M-$108.50M-$9.88M
Income tax-$1.10M$2.57M$338,000$0—
Net income-$38.63M-$72.70M-$135.35M-$108.50M-$73.96M
EBITDA-$45.85M-$72.99M-$137.09M-$108.64M-$70.75M
EPS (basic)————-2.96
EPS (diluted)————-2.96
Weighted avg. shares (diluted)83.07M73.91M51.40M47.23M25.00M
Balance sheet
Cash & equivalents$129.88M$229.12M$132.68M$60.19M$351.41M
Current assets$393.19M$377.44M$236.21M$275.89M$348.67M
PP&E, net$25.99M$29.48M$33.80M$27.07M$12.32M
Total assets$448.66M$438.73M$303.75M$342.39M$366.33M
Current liabilities$64.21M$156.95M$46.59M$25.57M$16.64M
Total liabilities$215.60M$215.80M$124.50M$70.98M$18.81M
Shareholders' equity$233.06M$222.94M$179.25M$271.41M$347.51M
Shares outstanding65.54M61.51M50.14M49.32M46.54M
Cash flow statement
Operating cash flow-$22.80M$42.00M-$43.80M-$92.47M-$59.36M
Capital expenditure$4.70M$3.99M$19.04M$12.91M$9.73M
Free cash flow-$27.50M$38.01M-$62.84M-$105.38M-$69.09M
Investing cash flow-$101.83M-$44.45M$88.80M-$219.22M-$9.65M
Financing cash flow$30.35M$98.89M$27.49M$20.47M$377.56M
Depreciation & amortization$8.36M$8.12M$6.22M$3.75M$2.13M
Stock-based compensation$18.86M$18.13M$16.67M$11.66M$5.20M
Dividends paid$0$0$0$0$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.